Approved & therapeutic
Ganirelix
Ganirelix Acetate, Fyremadel
Ganirelix is a GnRH antagonist used, like cetrorelix, to prevent premature LH surges in women undergoing controlled ovarian stimulation for assisted reproduction.
Also known as: Fyremadel, Orgalutran, Antagon, Ganirelix acetate
- Status
- Ganirelix is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- Approximately 13 hours after subcutaneous administration.
- How it's taken
- Subcutaneous injection into the abdomen or upper thigh
- Mechanism
- Reproductive axis (GnRH / kisspeptin / oxytocin)
- Pathways
- GnRH, Estrogen
How Ganirelix works
Ganirelix competitively occupies pituitary GnRH receptors, producing rapid, dose-dependent and reversible suppression of LH and FSH secretion without an initial stimulatory phase. Suppression reverses quickly on discontinuation, which is what allows the ovulation trigger to be timed precisely.
What research has looked at
- Prevents premature luteinising hormone surges during controlled ovarian stimulation.
- Rapid onset and rapid reversibility, so the cycle can be triggered on a chosen day.
- Supports the shorter antagonist protocol and permits a GnRH agonist trigger, lowering ovarian hyperstimulation syndrome risk relative to a long agonist protocol with hCG trigger.
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Ovarian hyperstimulation syndrome as part of the stimulation cycle.
- Injection-site reactions, typically mild and transient.
- Headache, nausea and abdominal pain.
- Hypersensitivity reactions, including reports of anaphylaxis with GnRH antagonists as a class.
- Contraindicated in pregnancy and in known hypersensitivity to GnRH or its analogues.
Sources
- FDA approved-drug listing for ganirelix · U.S. Food & Drug Administration
- DailyMed prescribing information for ganirelix · NIH · DailyMed
- PubMed research on ganirelix LH surge IVF · NIH · National Library of Medicine
- DrugBank record for ganirelix · DrugBank
Track Ganirelix in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Ganirelix FAQ
What is Ganirelix?
Ganirelix is a GnRH antagonist used, like cetrorelix, to prevent premature LH surges in women undergoing controlled ovarian stimulation for assisted reproduction.
How does Ganirelix work?
Ganirelix competitively occupies pituitary GnRH receptors, producing rapid, dose-dependent and reversible suppression of LH and FSH secretion without an initial stimulatory phase. Suppression reverses quickly on discontinuation, which is what allows the ovulation trigger to be timed precisely.
Is Ganirelix FDA approved?
Yes. Ganirelix is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Ganirelix?
Reported half-life: Approximately 13 hours after subcutaneous administration.
How is Ganirelix taken?
Subcutaneous injection into the abdomen or upper thigh.
What side effects have been reported with Ganirelix?
Reported in the sources: Ovarian hyperstimulation syndrome as part of the stimulation cycle; Injection-site reactions, typically mild and transient; Headache, nausea and abdominal pain; Hypersensitivity reactions, including reports of anaphylaxis with GnRH antagonists as a class; Contraindicated in pregnancy and in known hypersensitivity to GnRH or its analogues.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.